14 May 2021 : Original article
Nationwide Survey of Post-Transplant Glomerular Diseases, Based on the Japan Renal Biopsy Registry (J-RBR)
Joichi UsuiABCDEFG, Kunihiro YamagataABCDE, Michio NagataABCDE, Akira ShimizuBDE, Asami TakedaBDE, Hitoshi SugiyamaBDE, Hiroshi SatoBDE, Hitoshi YokoyamaBDEDOI: 10.12659/AOT.931873
Ann Transplant 2021; 26:e931873
Table 3 Characteristics of post-transplant glomerular diseases obtained from nationwide survey.
| Hariharan 1999 | Chailimpa-montree 2009 | An 2012 | Allen 2017 | Present study 2019 | ||
|---|---|---|---|---|---|---|
| Country | USA | Canada | Korea | Australia & NZ | Japan | |
| Number of renal transplants | (n) | 4913 | 2026 | 764 | 17 549 | 2 430 |
| Pre-transplant glomerular disease (Biopsy-proven) | (n, %) | |||||
| Total | NA | 734 | 195 | 6 597 | NA | |
| IgAN | NA | 246, 33.5 | 129, 66.2 | 2501, 37.9 | NA | |
| FSGS | NA | 196, 26.7 | 16, 8.2 | 1403, 21.3 | NA | |
| MGN | NA | 20, 2.7 | 4, 2.1 | 357, 5.4 | NA | |
| MPGN | NA | 42, 5.7 | 8, 4.1 | 376, 5.7 | NA | |
| Post-transplant glomerular disease (Biopsy-proven) | (n, %) | |||||
| Total | 167 | 94 | 70 | NA | 127 | |
| IgAN | 22, 13.2 | 45, 47.9 | 54, 77.1 | NA | 38, 29.9 | |
| FSGS | 57, 34.1 | 30, 31.9 | 8, 11.4 | NA | 8, 6.3 | |
| MGN | 16, 9.6 | 6, 6.4 | 2, 2.9 | NA | 0, 0.0 | |
| MPGN | 18, 10.8 | 5, 5.3 | 3, 4.3 | NA | 1, 0.8 | |
| Recurrence of glomerular disease | (n, %) | |||||
| Total | NA | 68 | NA | 553 | 33 | |
| IgAN | NA | 38, 55.9 | NA | 225, 40.7 | 26, 78.8 | |
| FSGS | NA | 19, 27.9 | NA | 144, 26.1 | 4, 12.1 | |
| MGN | NA | 2, 2.9 | NA | 49, 8.9 | 0, 0.0 | |
| MPGN | NA | 2, 2.9 | NA | 61, 11.0 | 0, 0.0 | |
| USA – United States of America; NZ – New Zealand; NA – not available; IgAN – immunoglobulin A nephropathy; FSGS – focal segmental glomerulosclerosis; MGN – membranous glomerulonephritis; MPGN – membranoproliferative glomerulonephritis. | ||||||